Evidence map›Paper›PMID 22101807›Full record

ReviewCancer metastasis reviews2012

Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Samar Masoumi Moghaddam, Afshin Amini, David L Morris, Mohammad H Pourgholami

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer metastasis reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 4 pooled it
10.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 4 syntheses or guidelines pooled it, 221 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Polydatin: A natural compound with multifaceted anticancer properties.Journal of traditional and complementary medicine · 2025
    Review
  15. Detecting vascular normalization in epithelial ovarian cancer.Medical oncology (Northwood, London, England) · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Alternative splicing in ovarian cancer.Cell communication and signaling : CCS · 2024
    Review
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Samar Masoumi MoghaddamDepartment of Surgery, University of New South Wales, Sydney, NSW, Australia, s.masoumimoghaddam@student.unsw.edu.au
Afshin Amini
David L Morris
Mohammad H Pourgholami
St George Hospital · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis which drives endothelial cell survival, proliferation, and migration while increasing vascular permeability. Playing an important role in the physiology of normal ovaries, VEGF has also been implicated in the pathogenesis of ovarian cancer. Essentially by promoting tumor angiogenesis and enhancing vascular permeability, VEGF contributes to the development of peritoneal carcinomatosis associated with malignant ascites formation, the characteristic feature of advanced ovarian cancer at diagnosis. In both experimental and clinical studies, VEGF levels have been inversely correlated with survival. Moreover, VEGF inhibition has been shown to inhibit tumor growth and ascites production and to suppress tumor invasion and metastasis. These findings have laid the basis for the clinical evaluation of agents targeting VEGF signaling pathway in patients with ovarian cancer. In this review, we will focus on VEGF involvement in the pathophysiology of ovarian cancer and its contribution to the disease progression and dissemination.

Indexed as

Neovascularization, PathologicAngiogenesis InhibitorsAnimalsAscitesFemaleHumansMolecular Targeted TherapyOvarian NeoplasmsPeritoneal NeoplasmsProtein Kinase InhibitorsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AAngiogenesis InhibitorsProtein Kinase InhibitorsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Identifiers

PMID22101807
PMCPMC3350632
OpenAlexW2041666177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.